Interx, Philochem and Scripps Research Announce A Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

InterX, Inc., a privately-owned company, Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, and Scripps Research, a non-profit American medical research facility, today announced the signature of a research collaboration to discover new small molecule therapeutics using InterX’s proprietary computational chemical biology software platform and Philochem’s and Scripps’ proprietary DNA-Encoded Chemical Library (DEL) technology.

This collaboration brings together Nobel laureates Roger Kornberg and Michael Levitt with leading DEL technology scientists Richard Lerner and Dario Neri. The team will collaborate on the development of a best-in-class targeting agent for metastatic prostate cancer, a disease that affects millions of patients worldwide.

Prof. Richard Lerner is Institute Professor at Scripps Research, one of the world’s leading Institutions in chemical and biomedical research. He first postulated the principle of DEL technology in 1992.

Philochem is a fully-owned subsidiary of the Philogen group, focused on the development of therapeutic products isolated from DNA-encoded chemical libraries. Philogen is a Swiss-Italian clinical-stage company, listed on the Italian stock exchange (Borsa Italiana). Philochem and Philogen were co-founded by Prof. Dario Neri (the Chief Executive Officer of the company), a pioneer in DEL research and a professor at ETH Zürich.